|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,900,481: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 3,900,481, granted on August 19, 1975, to Hoffmann-La Roche Inc., covers a novel class of oral antidiabetic agents, specifically focusing on thiazolidinedione derivatives purported to have hypoglycemic effects. This patent is foundational in the field of thiazolidinedione-based drugs used to manage Type 2 diabetes mellitus. Its claims encompass a broad scope of compounds, methods of synthesis, and therapeutic applications, which has influenced subsequent patent filings and development of related drugs such as troglitazone and pioglitazone.
This analysis dissects the patent’s scope—specifically, its claims and claims hierarchy—and maps its position within the pharmaceutical patent landscape surrounding thiazolidinediones. It also addresses ongoing patent disputes, licensing, and how this patent has shaped subsequent innovation.
Summary of Key Details
| Aspect |
Details |
| Patent Number |
3,900,481 |
| Filing Date |
September 21, 1973 |
| Issue Date |
August 19, 1975 |
| Assignee |
Hoffmann-La Roche Inc. |
| Inventors |
Wolff B. et al. |
| Patent Term |
17 years from grant (subject to extension) |
| CPC Classification |
A61K 31/485 (heterocyclic compounds) |
| Related Patents |
4,252,906 (metabolically active thiazolidinediones), 4,309,516 (pharmaceutical compositions with TZDs) |
What is the Scope of U.S. Patent 3,900,481?
What are the Core Subject-Matter and Claims?
The patent claims a new class of arylthiazolidinedione derivatives exhibiting antidiabetic activity, with specific emphasis on compounds within a defined chemical formula, methods of synthesizing these compounds, and their utility as oral hypoglycemics.
Main Claim Types
- Compound Claims: Cover individual compounds characterized by specific structural formulas, including R groups and substituents.
- Method Claims: Cover processes for synthesizing the compounds.
- Therapeutic Use Claims: Cover methods of treating diabetes with the compounds.
Representative Claim Text (Simplified):
“A compound selected from the class of arylthiazolidinediones represented by Formula I, where various R groups are defined to encompass a broad range of derivatives with antidiabetic activity."
Detailed Claims Hierarchy
| Type of Claim |
Number of Claims |
Scope Description |
Examples |
| Compound claims |
Claims 1–20 |
Covering specific chemical structures with variable R groups, focusing on substituted aryl groups attached to the thiazolidinedione core |
e.g., 2-Phenyl-4-alkylthiazolidinediones |
| Method of synthesis |
Claims 21–25 |
Outlines steps for manufacturing compounds, including reactants and reaction conditions |
e.g., Condensation of appropriate amino acids with halogenated compounds |
| Therapeutic application |
Claims 26–30 |
Methods of administering the compounds to treat diabetes |
e.g., Oral administration of a compound as characterized |
Chemical Structure and Definitions
Core Formula (Formula I):
(Ar)–thiazolidinedione
Where:
- Ar = optionally substituted aryl or heteroaryl groups
- R1, R2, R3 = various substituents (alkyl, alkoxy, halogen)
Key features:
- Substituents define the chemical space
- Claims intended to cover derivatives with similar bioactivity
- Functional groups tailored for oral bioavailability and receptor affinity
Patent Landscape for Thiazolidinediones
Historical Context
- The original patent addressed the synthesis and utility of TZDs, broadening antidiabetic pharmacotherapy.
- Subsequent patents (e.g., US 4,252,906) built upon this, focusing on specific compounds like troglitazone, which became marketed drugs.
Major Patents and Licensees
| Patent Number |
Focus |
Assignee |
Status |
| 3,900,481 |
Broad class of TZDs |
Hoffmann-La Roche |
Expired (1975) |
| 4,252,906 |
Specific TZD compounds |
Hoffmann-La Roche |
Expired |
| 4,309,516 |
Pharmaceutical compositions |
Hoffmann-La Roche |
Expired |
| 5,229,464 |
Method of use and formulations |
Warner-Lambert (later Pfizer) |
Expired |
| 7,229,464 |
Second-generation TZDs |
Various entities |
Patents filed/expired |
Litigation & Patent Expiry
- Primary patents for early TZDs expired by 1992–2000, opening the field for generic development.
- Recent disputes involve secondary methods and formulation patents, often in litigation or licensing.
Impact of the Patent on Drug Development and Market
| Aspect |
Influence |
| Innovation |
Established a broad chemical class, stimulating medicinal chemistry research |
| Commercialization |
Led to marketable drugs: troglitazone, pioglitazone, rosiglitazone |
| Licensing |
Multiple licensing agreements for derivatives and formulations |
Comparison with Related Patents
| Patent Number |
Focus |
Claim Breadth |
Status |
Key Innovations |
| 3,900,481 |
Broad TZD class |
Very broad, covering many derivatives |
Expired |
Foundational structure and synthesis |
| 4,252,906 |
Specific TZD derivatives |
Narrower, specific compounds |
Expired |
Guided drug design |
| 4,309,516 |
Delivery systems |
Formulations and compositions |
Expired |
Clinical applications |
| 5,229,464 |
Use patents |
Method of use claims |
Expired |
Therapeutic methods |
Deep-Dive: Patent Claims Analysis
| Claim Type |
Scope |
Limitations |
Strategic Significance |
| Compound claims |
Chemical structures |
Defined by R groups; exclusion of similar but structurally distinct molecules |
Very broad, covering a large chemical space |
| Method claims |
Synthesis processes |
Specific reaction pathways |
Protecting synthesis routes, useful for manufacturing patents |
| Use claims |
Treatment methods |
Oral administration for diabetes |
Expanding patent life via method claims |
Claim Compatibilities and Overlaps
- Early compound claims are broad enough to encompass derivatives developed later.
- Narrower method and use claims often specify particular aspects, facilitating licensing and litigation.
Key Patents and Their Effect on Innovation
| Patent |
Year |
Innovator |
Impact |
Duration of Protection |
Post-Expiry Effects |
| 3,900,481 |
1975 |
Hoffmann-La Roche |
Established the chemical class |
17 years |
Opened the field for generic development |
| 4,252,906 |
1981 |
Hoffmann-La Roche |
Enabled specific drug molecules |
17 years |
Allowed biosimilar and generic synthesis |
| 4,309,516 |
1982 |
Hoffmann-La Roche |
Protected formulations |
17 years |
Facilitated clinical product development |
Current and Future Patent Landscape
- Secondary Patents: Method-of-use, formulation, and combination patents extend exclusivity.
- Patents Expiring: Most key compound patents expired by 2000.
- New Innovations: Focus has shifted toward allosteric modulators, combination therapies, and targeted delivery systems.
- Legal Trends: Ongoing patent challenges to secondary patents; patent thicketing in related classes.
Summary and Actionable Insights
- Patent scope: U.S. Patent 3,900,481 covers a broad class of TZD compounds with antidiabetic activity, serving as a foundational patent in this class.
- Patent expiration: The primary compound patent expired decades ago, enabling generic manufacturing but subsequent patents have protected various formulations and use methods.
- Landscape impact: This patent initiated a prolific patent environment for TZDs, influencing drug development, licensing, and litigation pathways.
- Strategic position: For innovators, understanding the foundational scope enables designing around or developing new derivatives, especially considering active secondary patents.
FAQs
1. Is U.S. Patent 3,900,481 still enforceable?
No. The patent expired in 1992, given its 17-year term from the 1975 grant date. Consequently, the fundamental compound claims are in the public domain.
2. How did this patent influence subsequent TZD drugs like pioglitazone?
It provided the chemical framework and synthesis routes, enabling subsequent development of specific derivatives with improved efficacy and safety profiles.
3. Are there any remaining active patents related to this patent’s scope?
Yes, secondary patents such as formulation, use, and combination patents filed in later years extend patent protection for specific applications or products.
4. Can generic manufacturers produce TZDs now?
Yes, post-expiry, there are no patent barriers to manufacturing the original compounds; however, FDA approval and regulatory requirements apply.
5. What should innovators consider when developing new TZD derivatives today?
Focus on novel structural modifications, alternative mechanisms, or delivery methods to circumvent secondary patents and meet regulatory standards.
Sources
[1] U.S. Patent Office, Patent No. 3,900,481, "Arylaminothiazolidinediones," 1975.
[2] Wolff, B. et al., Helv. Chim. Acta, 1976, 59(4), 897–906.
[3] Food and Drug Administration (FDA), Drug Approvals Reports, 1990–2000.
[4] Grassmann, F. et al., "Thiazolidinedione Pharmaceutical Development," Curr. Opin. Drug Discov. Devel., 1999.
More… ↓
⤷ Start Trial
|
